Case 4: Recurrent Ovarian Cancer, Platinum-Resistant, BRCA WT
Case 4: I-O Therapy for Platinum-Resistant Recurrent DiseaseПодробнее
Case 4: Treating Platinum-Resistant Recurrent DiseaseПодробнее
Recurrent Ovarian Cancer: Third-Line Therapy and BeyondПодробнее
Diagnosis of Metastatic Platinum-Resistant Ovarian CancerПодробнее
Considerations for Managing Recurrent Ovarian CancerПодробнее
Case-Based Overview: Pretreated Recurrent Ovarian CancerПодробнее
Recurrent Ovarian Cancer: QUADRA TrialПодробнее
Emerging opportunities in platinum-resistant recurrent ovarian cancerПодробнее
Case 3: Maintenance Therapy for Recurrent Ovarian CancerПодробнее
Olaparib Maintenance for Recurrent Ovarian CancerПодробнее
Approaching Platinum-Refractory Recurrent Ovarian CancerПодробнее
Case 3: Second-Line Therapy for Recurrent Ovarian CancerПодробнее
Recurrent Ovarian Cancer: Novel Agents Under InvestigationПодробнее
Strategies for Managing Recurrent Ovarian CancerПодробнее
Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian CancerПодробнее
Factors in Choice of Treatment for Recurrent Ovarian CancerПодробнее
Case 3: PARP Inhibition in Recurrent Ovarian CancerПодробнее
Ovarian Cancer: Testing for BRCA MutationsПодробнее
Dr. Birrer Discusses Recurrent Ovarian Cancer TreatmentПодробнее
Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancerПодробнее